FASN and glioblastoma: Additionally, high levels of FASN predicted a poor prognosis following anti-PD-1 therapy according to Kaplan–Meier plotter analysis (Figure 6B), which was consistent with the prognosis of GBM patients receiving anti-PD-1 (Figure 6C).